GlucoTrack, Inc. filings document the regulatory, financial, and capital-structure disclosures of a medical technology company developing an implantable continuous blood glucose monitoring system for diabetes. Form 8-K reports cover Regulation FD releases on CBGM development, IDE-related disclosures, peer-reviewed study announcements, financial results, and corporate highlights.
The company’s filings also record material definitive agreements involving promissory-note exchanges for common stock, private-placement and exemption disclosures, beneficial-ownership limits, and shareholder voting matters. Proxy materials describe Nasdaq stock-issuance approvals, warrant-related share issuance proposals, meeting mechanics, governance procedures, and capital-structure matters tied to GlucoTrack’s public-company financing activities.
Glucotrack, Inc. has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration to begin a U.S. clinical study of its fully implantable continuous blood glucose monitoring (CBGM) technology.
The system is designed as a long-term, blood-based continuous glucose monitor with no on-body wearable component and a sensor longevity of 3 years, aiming to provide real-time glucose data in a comfortable and discreet form. The IDE submission follows several years of engineering, preclinical evaluation, and iterative design work, and Glucotrack plans to proceed with the U.S. clinical study following FDA review and approval.
Glucotrack, Inc. entered into an Exchange Agreement to swap a $988,000 partitioned promissory note for 1,300,000 shares of its common stock. This is a debt-for-equity exchange with no cash paid by the investor, which reduces note principal while increasing the share count.
The issuance is subject to a 19.9% beneficial ownership limitation, so shares may be issued in tranches and any unexchanged portion of the note will remain outstanding. The company also furnished an updated investor presentation as an exhibit.
Glucotrack, Inc. reported new peer-reviewed data on its fully implantable continuous blood glucose monitoring (CBGM) system from an in-vivo ovine study. Thirty-four devices implanted in 17 adult sheep were followed for up to 240 days and achieved a weighted average Mean Absolute Relative Difference (MARD) of 6.8% across 79 intravenous glucose tolerance tests, indicating high accuracy, with no device-related adverse safety events observed.
The company noted that these preclinical results, together with prior first-in-human data showing a MARD of 7.7% with 99% data capture and no procedure- or device-related serious adverse events, help support its planned IDE submission to the FDA and continued clinical development of its long-life CBGM platform.
Glucotrack, Inc. files a Post-Effective Amendment to its Form S-1 registering up to 20,060,000 shares of Common Stock for resale by Sixth Borough Capital Fund, LP. The registration covers up to 20,000,000 Purchase Shares tied to a purchase agreement that could provide up to $20.0 million in committed equity financing and 60,000 Commitment Shares issuable on exercise of pre-funded warrants. As of April 27, 2026, Glucotrack had 3,659,279 shares outstanding and a last reported Nasdaq sale price of $0.72 per share. The company controls timing of any sales to Sixth Borough and would receive proceeds only if it elects to sell Purchase Shares under the Purchase Agreement.
Glucotrack, Inc. entered into an Exchange Agreement with an investor to convert a portion of existing debt into equity. The company carved out a new promissory note with an original principal of $600,000, called the Partitioned Note, from a prior $3,600,000 promissory note.
This Partitioned Note will be exchanged for 895,000 shares of common stock, with no cash paid by the investor. Issuance is subject to a 19.9% beneficial ownership limitation, so shares may be delivered in tranches and any remaining balance of the Partitioned Note will stay outstanding until it can be exchanged.
The Partitioned Note was issued under a private placement exemption in Section 4(a)(2), and the exchange shares rely on the Section 3(a)(9) exemption, meaning they are issued solely in exchange for outstanding company securities without additional consideration or commissions.
Glucotrack, Inc. files its annual report describing a development-stage medical device business focused on an implantable continuous blood glucose monitor (Glucotrack CBGM) for Type 1 and insulin-using Type 2 diabetes patients.
The company reports multiple successful preclinical and early human studies, ISO 13485 certification, and active FDA presubmission discussions toward an Investigational Device Exemption and a planned U.S. feasibility study in 2026. It highlights a large global diabetes market and unmet needs around convenience, wear-time, and comfort versus current CGM systems.
Financially, Glucotrack remains pre-revenue with net losses of about $19.4 million in 2025 and an accumulated deficit of $151.8 million, ending 2025 with $7.4 million in cash. Management and auditors raise substantial doubt about the company’s ability to continue as a going concern without additional capital, and the filing emphasizes significant regulatory, clinical, competitive, and reimbursement risks.
Glucotrack, Inc. reported its fourth quarter and full year 2025 results and highlighted progress on its implantable continuous blood glucose monitoring (CBGM) technology. The company plans to file an Investigational Device Exemption (IDE) with the FDA in the second quarter of 2026, targeting a U.S. clinical trial launch in the second half of 2026, subject to IDE approval.
In December 2025, Glucotrack raised approximately $4.0 million in gross proceeds through the sale of 1,033,591 shares of common stock (or equivalents) and warrants to purchase up to 2,067,182 shares at a combined effective price of $3.87. For full year 2025, research and development expenses were $9.8 million versus $9.5 million in 2024, and general and administrative expenses were $6.3 million versus $5.1 million.
The 2025 net loss was $19.4 million, improving from a net loss of $22.6 million in 2024, largely due to prior-year non-cash losses. Cash and cash equivalents were $7.4 million at December 31, 2025, up from $5.6 million a year earlier. Management believes existing cash will fund its 2026 operating plan through spring, including the IDE submission and initiation of U.S. human clinical trials.
Glucotrack, Inc. outlined clinical and operational progress that supports its plan to submit an Investigational Device Exemption (IDE) to the FDA for its implantable continuous blood glucose monitoring (CBGM) system in Q2 2026, aiming to start a U.S. clinical trial in the second half of 2026, subject to FDA approval.
The company completed a 5‑day first‑in‑human study in Brazil with 10 participants, achieving a Mean Absolute Relative Difference of 7.7% across 122 matched pairs, 99% data capture, and no procedure or device‑related serious adverse events. A follow‑on feasibility trial in Australia produced similar performance and informed protocol and product refinements.
Glucotrack also secured a U.S. trial site, engaged a CRO experienced in diabetes medtech, and completed targeted design iterations. In 2025 it was awarded three U.S. patents (US 12,453,494; US 12,458,257; US 12,458,258) covering sensor chemistry, intravascular lead design, and low‑power electronics for its three‑year longevity CBGM platform.
Glucotrack, Inc. held a special shareholder meeting where investors approved several key proposals related to future stock issuances and auditor ratification. As of the January 28, 2026 record date, 1,011,279 common shares were outstanding, and 446,348 votes (about 44.1%) were represented, forming a quorum.
Shareholders approved a Nasdaq Stock Issuance (ELOC) Proposal authorizing the full issuance of shares of common stock to Sixth Borough Capital Fund, LP under a September 11, 2025 purchase agreement, which may exceed 20% of shares outstanding on that date. They also approved the Nasdaq Stock Issuance (Warrants) Proposal for the full issuance of shares underlying 2,067,182 common warrants from a December 31, 2025 private placement, with 26,134 votes for and 18,151 against after excluding 100,591 ineligible shares.
In addition, shareholders ratified the appointment of CBIZ CPAs P.C. as independent auditor for the year ended December 31, 2025, with 431,871 votes in favor. An adjournment proposal was not needed because all principal proposals received sufficient support.